BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11919245)

  • 41. A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
    Gupta SK; John S; Naik R; Arora R; Selvamani B; Fuloria J; Ganesh N; Awasthy BS
    Gynecol Oncol; 2005 Jul; 98(1):134-40. PubMed ID: 15894360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
    Greco FA; Burris HA; Litchy S; Barton JH; Bradof JE; Richards P; Scullin DC; Erland JB; Morrissey LH; Hainsworth JD
    J Clin Oncol; 2002 Mar; 20(6):1651-6. PubMed ID: 11896116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
    Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
    Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
    Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
    Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
    Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
    du Bois A; Herrstedt J; Hardy-Bessard AC; Müller HH; Harter P; Kristensen G; Joly F; Huober J; Avall-Lundqvist E; Weber B; Kurzeder C; Jelic S; Pujade-Lauraine E; Burges A; Pfisterer J; Gropp M; Staehle A; Wimberger P; Jackisch C; Sehouli J
    J Clin Oncol; 2010 Sep; 28(27):4162-9. PubMed ID: 20733132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
    Shepard RC; Levy DE; Berlin JD; Stuart K; Harris JE; Aviles V; Thomas JP; Benson AB
    Oncology; 2004; 66(4):303-9. PubMed ID: 15218298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.
    Møller AK; Pedersen KD; Gothelf A; Daugaard G
    Acta Oncol; 2010 May; 49(4):423-30. PubMed ID: 20397773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
    Hainsworth JD; Burris HA; Greco FA
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):21-5. PubMed ID: 11441411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
    Bhatia S; Hanna N; Ansari R; Pletcher W; Einhorn L; Ng E; Sandler A
    Lung Cancer; 2002 Oct; 38(1):73-7. PubMed ID: 12367796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
    Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
    J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
    Greggi S; Salerno MG; D'Agostino G; Ferrandina G; Lorusso D; Manzione L; Mancuso S; Scambia G
    Oncology; 2001; 60(1):19-23. PubMed ID: 11150903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
    Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
    Xu B; Shen Z; Jiang Z; Guan Z; Zhang X
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):320-9. PubMed ID: 21114782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.